{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-043229","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.530722+00:00","generated_at":"2026-06-01T22:40:56.598459+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ABVC BioPharma licenses BLEX 404 for TNBC to OncoX in deal worth up to $13.75M plus royalties","bullets":["Definitive license agreement with OncoX BioPharma for exclusive rights to develop and commercialize BLEX 404 for TNBC in 50% of worldwide markets for 20 years.","Total license fee of $6.25M (or 1.25M OncoX shares at $5/share) due 30 days after signing; additional milestone of $625k cash after OncoX's next fundraising (no guarantee).","ABVC and its subsidiary BioLite each signed identical agreements; aggregate potential payments including royalties up to $13.75M (press release states $12.5M license fee and $1.25M milestone).","Royalties of 5% of net sales on licensed product, up to $12.5M, starting from first commercial sale (uncertain).","US FDA has approved four INDs for ABVC's BLEX 404 combination therapy, including for TNBC (IND 129575)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-043229","json":"https://secwatch.observer/filing/0001213900-24-043229.json","markdown":"https://secwatch.observer/filing/0001213900-24-043229.md","text":"https://secwatch.observer/filing/0001213900-24-043229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/0001213900-24-043229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/ea0206070-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:40:56.598459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10e712aca32e69577cc61a041ddbeccbd0353727","claim":"ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p (effective 2024-05-14).","evidence_excerpt":"On May 14, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC’s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the “ Licensed Products ”), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the “ Oncox Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/0001213900-24-043229-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"OncoX BioPharma, Inc."},{"label":"Value","value":"Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}